Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027635 | 0.90 | ADRA2C (0.50) | ADRA2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL16675693 | 0.90 | ADRA2C (0.50) | ADRA2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL10127797 | 0.84 | ADRA2C (0.64) | ADRA2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL17754015 | 0.83 | ADRB1 (0.56) | MAPTALDH1A1NSD2SETD2NPY5R | |
| SCHEMBL2174889 | 0.82 | NPY5R (0.53) | ALDH1A1NSD2SETD2TMEM97SIGMAR1 | |
| SCHEMBL22837867 | 0.82 | NPY5R (0.54) | NSD2SETD2NPY5REED | |
| SCHEMBL22837816 | 0.82 | HTR3E (0.55) | MAPTALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL1409679 | 0.81 | MAPT (0.53) | ADRA2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL14578437 | 0.81 | ADRA2C (0.62) | ADRA2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL21447979 | 0.80 | L3MBTL3 (0.52) | ALDH1A1MEN1ALOX15KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514153-B1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HANMI PHARM IND CO LTD (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3789386-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2021-03-10 | — | — | EP | disclosed |
| EP-3514153-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2019-07-24 | — | — | EP | disclosed |
| US-20190031643-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | ADRA2C 105/4885MAPT 3687/4885ALDH1A1 279/4885 |
| US-20190031643-A1 | PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | TYMP, DPYD, TYMS | ADRA2C 3511/4885MAPT 3081/4885ALDH1A1 389/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | ADRA2C 64/4885MAPT 3546/4885ALDH1A1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.